SILVER SPRING, Md. - FDA advisers Wednesday said the response rate and duration of response from Allos Therapeutics Inc.'s single-arm study were reasonably likely to predict the clinical benefit of Folotyn (pralatrexate) in treating patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). (BioWorld Today)